Di fronte al progressivo aumento dell’incidenza delle infezioni dovute alla variante SARS-CoV-2 Omicron (B.1.1. 529), rimane alta l’allerta sulla capacità di rilevare in modo efficace questa nuova forma virale con mutazioni multiple del virus COVID-19.
I test molecolari bioMérieux rilevano la variante SARS-CoV-2 Omicron
02 Dicembre, 2021
bioMérieux – Risultati finanziari del primo semestre 2021
09 Settembre, 2021
Il Consiglio di amministrazione di bioMérieux, leader mondiale nel campo della diagnostica in vitro, comunica i dati finanziari relativi al primo semestre 2021.
bioMérieux – Business Review del primo trimestre 2021
27 Aprile, 2021
bioMérieux, leader globale nella diagnostica in vitro comunica la business review per il trimestre conclusosi il 31 Marzo 2021.
bioMérieux announces the CE marking of 3 dengue immunoassays on VIDAS®
07 Aprile, 2021
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated assays to diagnose dengue infection: VIDAS® DENGUE NS1 Ag VIDAS® Anti-DENGUE IgM VIDAS® Anti-DENGUE IgG
BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization
18 Marzo, 2021
Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel.
bioMérieux – 2020 Financial Results
24 Febbraio, 2021
bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.
17 Novembre, 2020
Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
First-Half 2020 Results
02 Settembre, 2020